Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Cost of Revenue: 2017-2025

Historic Cost of Revenue for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $3.3 million.

  • UroGen Pharma's Cost of Revenue rose 33.63% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 33.73%. This contributed to the annual value of $8.9 million for FY2024, which is 5.13% down from last year.
  • Per UroGen Pharma's latest filing, its Cost of Revenue stood at $3.3 million for Q3 2025, which was down 7.66% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Cost of Revenue ranged from a high of $3.5 million in Q2 2025 and a low of $897,000 during Q1 2021.
  • For the 3-year period, UroGen Pharma's Cost of Revenue averaged around $2.5 million, with its median value being $2.4 million (2023).
  • In the last 5 years, UroGen Pharma's Cost of Revenue soared by 302.59% in 2021 and then fell by 23.71% in 2024.
  • UroGen Pharma's Cost of Revenue (Quarterly) stood at $1.6 million in 2021, then surged by 42.42% to $2.3 million in 2022, then rose by 1.02% to $2.3 million in 2023, then rose by 8.09% to $2.5 million in 2024, then surged by 33.63% to $3.3 million in 2025.
  • Its Cost of Revenue stands at $3.3 million for Q3 2025, versus $3.5 million for Q2 2025 and $2.3 million for Q1 2025.